News 2017-10-24T15:08:32+00:00

Proteon Pharmaceuticals attracts environmental impact investment fund

October 24, 2017  - Proteon Pharmaceuticals S.A., a Polish biotechnology firm has signed an agreement with an international Investment Fund, the Aqua-Spark fund, which invests in sustainable aquaculture. Proteon Pharmaceuticals will use the funds to commercialize its products globally, develop production capacity and support the development of its bacteriophage-platform technology. Proteon Pharmaceuticals is a world leader [...]

By |

BAFADOR® presented at the international bacteriophage conference in Tbilisi

Proteon Pharmaceuticals presents its unique product BAFADOR® at the international bacteriophage conference in Tbilisi Proteon Pharmaceuticals participated in the international conference “Centennial Celebration of Bacteriophage Research”, held in Tbilisi, Georgia on June 26-29, 2017. Proteon Pharmaceuticals’ R&D Director, Dr Ewelina Wójcik, presented the results of Company’s research, which has led to development of a phage-based solution [...]

By |

Proteon Pharmaceuticals awarded grants for Euro 3.2 m

In 2016 Proteon Pharmaceuticals awarded grants from Polish Center for Research & Development for Euro 3.2 m In 2016, Proteon Pharmaceuticals signed the agreements for the co-financing five research projects from the European Union for Euro 3.2 million. The projects are for research and development of new generation, innovative products, based on our unique phage-platform technology. [...]

By |



Proteon Pharmaceuticals S.A.

ul. Tylna 3a 90-364 Lodz, POLAND

Phone: +48 502-269-383

Mobile: +48 502-678-674

Fax: +48 42-209-33-96